Delving into the Latest Updates on Lebrikizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

ANTI-IL-13, Lebrikizumab (genetical recombination) (JAN), Lebrikizumab (USAN/INN)

+ [13]

Target

IL-13

Action

inhibitors

Mechanism

IL-13 inhibitors(Interleukin-13 inhibitors)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [3]

Active Indication

Dermatitis, AtopicChronic rhinosinusitis with nasal polypsRhinitis, Allergic, Perennial+ [3]

Inactive Indication

airway diseaseAirway ObstructionAllergic asthma+ [4]

Originator Organization

Genentech, Inc.

Active Organization

Eli Lilly & Co.

Almirall SAEli Lilly Japan KK

+ [3]

Inactive Organization

Hoffmann-La Roche, Inc.Tanox, Inc.

License Organization

+ [1]

Drug Highest PhaseApproved

First Approval Date

European Union (16 Nov 2023),

Dermatitis, Atopic

RegulationFast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 142719L

Source: *****

Sequence Code 9082543H

Source: *****

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis.
This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.

Start Date01 Apr 2025

Sponsor / Collaborator

Eli Lilly & Co.

NCT06906497

/ Not yet recruitingPhase 4IIT

Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis

This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

Start Date01 Apr 2025

Sponsor / Collaborator

University of Michigan

[+2]

DRKS00036456

/ RecruitingNot ApplicableIIT

Modulation of specific IgE’s in patients with atopic dermatitis under the treatment with Lebrikizumab - IGELEBRI

Start Date13 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lebrikizumab

Login to view more data

100 Translational Medicine associated with Lebrikizumab

Login to view more data

100 Patents (Medical) associated with Lebrikizumab

Login to view more data

184

Literatures (Medical) associated with Lebrikizumab

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Article

Author: Augustin, M. ; Wagner, J. N. ; Zirkenbach, F. ; Grote, C.

PURPOSE:

Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.

MATERIAL AND METHODS:

This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.

RESULTS:

Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.

CONCLUSIONS:

This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.

04 May 2025·Expert Opinion on Drug Delivery

Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab

Article

Author: Veilleux, Jean-Christophe ; Shi, Galen H ; Tavakolian, Milad ; Vlachos, Pavlos P ; Eshraghi, Javad ; Duffy, Kevin H ; Derakhshandeh, Rozhin

BACKGROUND:

Design parameters of prefilled pens, known as autoinjectors within the medical device community, can affect pen's functioning and user experience. This study compares the performance of two 2 mL prefilled pen devices: lebrikizumab (125 mg/mL) and dupilumab (150 mg/mL).

RESEARCH DESIGN AND METHODS:

We recorded force and acoustic signals during administration from the prefilled pen devices and performed high-speed video recording during needle insertion and drug delivery. Measurements were reported in these categories: (i) The kinematics of needle movement during insertion captured by two cameras (ii) Injection flow rate and duration, and the time between acoustic 1st (activation) click and 2nd click sounds (iii) Post-2nd click injection duration, and (iv) delivered dose volume. We investigated the impact of temperature on device performance by experimenting at room temperature (~25℃) and cool condition (~5℃).

RESULTS:

The lebrikizumab device demonstrated faster injection and more reliable end-of-dose indication, while the dupilumab device showed less lateral needle movement in air during insertion. The device activation forces are provided.

CONCLUSION:

Our investigation uncovered performance distinctions between lebrikizumab and dupilumab prefilled pens, which could potentially translate into patient experience, and varying levels of risk associated with intramuscular injection for the adult population and premature device removal.

01 May 2025·Journal of Allergy and Clinical Immunology-In Practice

Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors

Article

Author: Paller, Amy S ; Sun, Dingyuan I ; Kamata, Masahiro

Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder associated with reduced quality of life related to itch, sleep disturbance, risk of cutaneous infections, mental health issues, and high caregiver stress. Biologics and Janus kinase (JAK) inhibitors are transformative treatments for moderate-to-severe AD, providing options for patients unresponsive to conventional topical therapies. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are injectable biologics that offer durable control by targeting the underlying skewing to type 2 inflammation. Dupilumab, the first available biologic, is approved for patients as >6 months old and concurrently manages atopic comorbidities, particularly allergic asthma. In contrast, JAK inhibitors-upadacitinib, abrocitinib, and baricitinib-are oral therapies, offering rapid relief of inflammation and pruritus by inhibiting the JAK-STAT (signal transducer and activator of transcription) pathway, which is downstream of type 2 immune receptors. JAK inhibitors are approved for >12 years old in the USA, but in other geographic regions for those >2 years of age (baricitinib). This review highlights key considerations for selecting among these advanced therapies, including age, comorbidities, efficacy, and safety profiles. By integrating the latest evidence, this article provides a practical guide for clinicians to tailor treatment approaches and improve outcomes for individuals with AD.

153

News (Medical) associated with Lebrikizumab

20 May 2025

·www.fiercepharma.com

As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings

Eli Lilly and AstraZeneca landed at the top of IDEA Pharma's annual Innovation Index and Invention Index rankings, respectively. As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ranks (PDF) the most transformative companies in the biopharma industry.While Lilly advanced from fourth place in 2024 to the top spot this year, it has supplanted last year's champion Novo, which tumbled all the way to eighth place. It’s a familiar perch for Lilly, which earned IDEA’s No. 1 slot in 2019 and 2021.This is the 14th year that IDEA, a pharmaceutical industry consulting firm based in London, has conducted the analysis. In 2019, IDEA added an annual Invention Index, which was topped by AstraZeneca for the third time in the last four years.In conducting its Innovation ranking, IDEA asks two questions: Who in the industry is at the forefront of innovation and what are they doing to achieve this? Additionally, if two biopharma companies were given the same molecule in early phase, which would better develop and launch it and why?In ranking Lilly No. 1, IDEA cited the FDA approvals of obesity drug Zepbound for obstructive sleep apnea, Kisunla for Alzheimer’s disease and Ebglyss for atopic dermatitis, each of which came in the second half of 2024.IDEA also recognized Lilly’s $3.2 billion buyout of Morphic to expand its immunology portfolio and its creation of the LillyDirect platform, which “reflects the company’s commitment to improving patient access and affordability by streamlining therapy delivery and reducing insulin costs.”On the flip side, in addition to falling into No. 8 on the Innovation Index, Novo plummeted to last place in the Invention Index. In both categories, IDEA ranks the industry’s top 30 companies.Novo’s declining fortunes are reflected in a market cap slide from $640 billion in July of last year to its present figure of $293 billion. Last week, the company announced the departure of eight-year CEO Lars Fruergaard Jørgensen. Also receiving high marks in the Innovation rankings were No. 2 Merck, which jumped from the 10th slot largely because of the continued progression of the development of megablockbuster Keytruda. Third-place AZ and fourth-place Roche rose from Nos. 7 and 8, respectively, while Pfizer, which claimed consecutive titles in 2022 and 2023 for its rapid development of COVID-19 products, came in at No. 5. Also making notable jumps were No. 6 Regeneron, from 15th place, No. 7 UCB, which vaulted from outside of the top 20, and No. 10 Novartis, which was up from 17th place.UCB’s leap was fueled by “significant advancements in immunology, neurology and rare diseases,” IDEA wrote, citing advancements with Bimzelx in inflammatory conditions. "With a pipeline that spans high-need therapeutic areas, UCB has re-established itself as a resilient and innovative player, leveraging differentiated biologics and cutting-edge research to address unmet patient needs,” IDEA CEO Mike Rea said in a release.While IDEA’s Innovation Index measures how well companies perform in bringing new medicines to market and commercializing them, its Invention Index examines the breadth and depth of novel agents currently being developed within the top 30 pharma pipelines. The Invention Index provides a more forward-looking view of who is developing medicines that matter, embracing science and innovations in R&D. AZ’s recent dominance of the category is owed to its deep portfolio across several disease areas, including oncology, evidenced by the success and additional potential of blockbusters Tagrisso, Imfinzi and Enhertu across multiple cancer types.AZ replaced Johnson & Johnson in the top spot, with J&J falling to second place this year, one notch in front of Moderna. As they did in the Innovation Index, Roche and Regeneron also made significant leaps, from No. 17 and No. 8, respectively, last year, to tie for fourth place. Jumping from the teens into the top 10 were No. 8 GSK, as well as BeiGene and Boehringer Ingelheim, which tied for 10th place. Others in the Invention Index top 10 were No. 6 Lilly, No. 7 Merck and No. 9 Pfizer.In addition to Novo placing last in the Invention Index, others who performed poorly in the rankings were Merck KGaA, which placed No. 30 in Innovation and No. 26 in Invention. Takeda also was in the bottom five in both categories. Bayer, Biogen, AbbVie and Otsuka were in the bottom 10 in both categories.

AcquisitionDrug Approval

17 Mar 2025

·www.pharmaceutical-technology.com

Incyte stock hit 11% despite paediatric dermatology trials hitting target

The US-based company’s Stop-HS1 and Stop-HS2 trials hit their primary endpoints with both doses of povorcitinib. Credit: Shutterstock / Kristi Blokhin. Incyte’s stock price has taken a hit of more than 11%, despite two Phase III trials investigating its oral small-molecule JAK1 inhibitor in hidradenitis suppurativa (HS) hitting their primary endpoints. The US-based company’s Stop-HS1 (NCT05620823) and Stop-HS2 (NCT05620836) trials hit their primary endpoints with both doses of povorcitinib, 45mg and 75mg, with a higher proportion of patients treated with the therapy. This achieved a Hidradenitis Suppurativa Clinical Response (HiSCR), which is defined as more than 50% from baseline in the total abscess and inflammatory nodule count. After 12 weeks of treatment, in the Stop-HS1 trial, 40.2% of patients receiving 45mg povorcitinib saw HiSCR versus 29.7% in the placebo group while patients in the 75mg cohort saw similar results with 40.6% achieving HiSCR. Results in the Stop-HS2 trial saw similar rates with patients in the 45mg group seeing 42.3% HiSCR rates versus the same percentile in the 75mg group. At the same time, the trials met key secondary endpoints, including the proportion of patients achieving a 75% reduction in inflammatory nodule count. Both studies included a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and a 30-day safety follow-up period. Despite this, the company’s stock price has taken a hit of more than 11%, dropping from $67.72 before the announcement, down to $60.72 per share at the time of publication (11am EST, 17 March). The studies each enrolled approximately 600 children across more than 100 international sites diagnosed with moderate to severe HS for at least three months before a screening visit, who presented with more than five lesions in at least two different anatomical areas. Incyte’s chief medical officer Steven Stein said: “HS is a challenging and debilitating condition without a cure. Given the limitations of current HS treatments and their impact on patients’ daily lives, there is a critical need for new, well-tolerated and effective therapies that provide a rapid reduction in the signs and symptoms of HS, in particular, pain. “The positive Phase III data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS.” Assuming povorcitinib makes it to market, research by GlobalData’s Pharmaceutical Intelligence Center estimates that it is likely to bring in $34m by the end of 2026, with that figure estimated to rise to $625m by the end of 2030. GlobalData is the parent company of Clinical Trials Arena . The company is now planning to use these results to advance regulatory submissions worldwide. Away from HS, the company is examining povorcitinib in a Phase III trial in vitiligo, as well as an ongoing Phase II trial in asthma. Elsewhere in the field of skin conditions, Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD). Meanwhile, Bambusa Therapeutics has announced the dosing of its first healthy volunteers as part of a Phase I trial on its half-life extended bispecific antibody therapy for AD.

Phase 3Clinical ResultPhase 2Phase 1Immunotherapy

10 Mar 2025

·www.fiercebiotech.com

Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect

Amgen paid Kyowa Kirin $400 million upfront for rights to rocatinlimab in 2021.\n Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi and Regeneron’s Dupixent remain unanswered.Last year, Amgen and Kyowa shared the first data from its broad phase 3 rocatinlimab program. The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area and severity after 24 weeks of treatment. The comparable figures from Dupixent trials are as high as 36% after 16 weeks.Amgen sees an opportunity for a drug with a different mechanism of action, citing evidence about how often patients stop or switch therapies. Saturday, the Big Biotech and Kyowa presented results to make the case that rocatinlimab can seize that opportunity.The latest data come from Ignite and Shuttle, two trials from Amgen and Kyowa’s broader Rocket program. Ignite randomized 769 adults with moderate to severe eczema, including an undisclosed number of patients previously treated with a biologic or systemic JAK inhibitor, to receive one of two doses of rocatinlimab or placebo. The high dose was identical to the only dose used in the earlier phase 3 trial. On the high dose, 42.3% of patients met the 75% improvement criteria, EASI-75. The placebo-adjusted EASI-75 was 29.5%. The lower dose was less effective, but the result was still numerically higher than in the earlier phase 3, with a placebo-adjusted difference of 23.4%. Jefferies analysts said in a note to investors that the results are “optically more compelling” than the earlier data.The other study, Shuttle, randomized 746 adults with moderate to severe eczema to receive one of two doses of rocatinlimab or placebo. Again, the high dose was the same dose used in the earlier phase 3 trial. Participants in Shuttle also received topical corticosteroids and/or topical calcineurin inhibitors. The placebo-adjusted EASI-75 results were 28.7% and 30.4%, respectively, on the low and high doses.Amgen, which paid Kyowa $400 million upfront for rights to rocatinlimab in 2021, also reported wins on two versions of an investigator eczema assessment scale in Ignite and Shuttle. Safety was generally consistent with the profile seen in earlier studies, according to Amgen and Kyowa.“In totality, the rocatinlimab results validate the OX40 mechanism, likely supporting a moderate commercial opportunity for patients after Dupixent/Ebglyss,” William Blair analysts said in a March 10 note.However, the readouts “still leave potential room for improvement with future OX40/OX40L targeting therapies,” added the analysts, pointing to Inmagene\'s OX40-targeting monoclonal antibody IMG-007.Three more readouts are coming up. Amgen and Kyowa are aiming to publish phase 3 results from Ascend, a trial that is assessing dosing beyond 24 weeks, and the adolescent Astro study in the second half of the year. A second trial in adolescent patients, Orbit, is underway, as are phase 2 and 3 trials in asthma and prurigo nodularis. The studies are testing the idea that rocatinlimab rebalances the T-cell compartment.

Phase 3Clinical ResultPhase 2Phase 1Financial Statement

100 Deals associated with Lebrikizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09633	Lebrikizumab	-	DB11914

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	European Union	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Iceland	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Liechtenstein	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Norway	Almirall SA	16 Nov 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic rhinosinusitis with nasal polyps	Phase 3	United States	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	China	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Japan	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Belgium	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Bulgaria	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Canada	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Denmark	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Germany	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Italy	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Poland	Eli Lilly & Co.	29 Apr 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05369403 (ADapt, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	86	Lebrikizumab (Lebrikizumab 250mg Q2W)	dfpoydfdye = judpmkypmf yqqwlooowq (wqfefgmfse, vsrwpcwiin - ybvrbzzmdg) View more	-	19 Mar 2025
				Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W)	rhgfyvruvv = idpcrpmjve bpdmspmxhn (jnwcxahxlb, pebvidjvjd - camyjxyrxg) View more
NCT04146363 \| NCT04178967 (Pubmed)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	-	Lebrikizumab	pjqldgruei(scdxromelf) = significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders msflbpznum (gvujjwfwmj )	Positive	31 Dec 2024
NCT04760314 (ADhere-J, Pubmed) Manual	Phase 3	Dermatitis, Atopic	286	Placebo + TCS	cvfijltgng(mxanhuehwg) = mvztjogdpj lskbtymyng (npsitadyda ) View more	Positive	03 Dec 2024
				Lebrikizumab 250 mg Q4W + TCS	cvfijltgng(mxanhuehwg) = ouyslkwtfn lskbtymyng (npsitadyda ) View more
NCT04840901 (CTgov)	Phase 1	-	242	Lebrikizumab (Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD))	ooddissqro(ozrakglyfs) = epatodbqks kgsxlehjjd (jaebhouqps, 31) View more	-	22 Nov 2024
				Lebrikizumab (Test) (Lebrikizumab (Test) - Autoinjector (AI))	ooddissqro(ozrakglyfs) = wakgnjmzxw kgsxlehjjd (jaebhouqps, 31) View more
NCT04760314 (Pubmed) Manual	Phase 3	Dermatitis, Atopic	271	lebrikizumab + topical corticosteroids (TCS) (maintenance primary population)	fzkjsskpxi(xcvrxekqcs) = ypqryxvhdu pmdzzykwxt (ravljkxvqd ) View more	Positive	23 Oct 2024
				lebrikizumab + topical corticosteroids (TCS) (maintenance escape population)	fzkjsskpxi(xcvrxekqcs) = okwndoztbj pmdzzykwxt (ravljkxvqd ) View more
NCT04146363 \| NCT04178967 (FDA_CDER) Manual	Phase 3	Dermatitis, Atopic	851	EBGLYSS 250 mg Q2W (ADvocate 1)	ryruetqunb(llbbeevcpx) = loaxdoawkf goemmitlia (tuehsoagjq ) View more	Positive	13 Sep 2024
				Placebo (ADvocate 1)	ryruetqunb(llbbeevcpx) = zznbyhdihp goemmitlia (tuehsoagjq ) View more
NCT04146363 \| NCT04178967 (ADvocate2, Pubmed \| Adv Ther) Manual	Phase 3	Dermatitis, Atopic	-	Lebrikizumab 250 mg	hbjqhhdrhq(icvscpzywl) = eullhkwqwu vkgnsvgeai (unlrkslwee ) View more	Positive	09 Sep 2024
				Placebo	hbjqhhdrhq(icvscpzywl) = vqikyqlxog vkgnsvgeai (unlrkslwee ) View more
NCT04146363 \| NCT04178967 (ADvocate1;ADvocate2, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Severe Atopic Dermatitis Maintenance	-	Lebrikizumab Q2W	qagypogpmb(ieoummgwut) = cfgbmtlpfe gmapbbszva (vujgwaebne ) View more	Positive	01 Aug 2024
				Lebrikizumab Q4W	qagypogpmb(ieoummgwut) = wvrhlrovdu gmapbbszva (vujgwaebne ) View more
NCT04626297 (ADopt-VA, Pubmed)	Phase 3	Severe Atopic Dermatitis	106	Lebrikizumab 250 mg every 2 weeks	okfzfwadgl(hdlhyziecr) = uyoijrlezl oumastkcmb (hcelyuohgh ) View more	Positive	15 Jul 2024
				Placebo	okfzfwadgl(hdlhyziecr) = yfoaskdcbp oumastkcmb (hcelyuohgh ) View more
NCT04146363 \| NCT04178967 (ADvocate1;ADvocate2, Pubmed)	Phase 3	Dermatitis, Atopic	-	Lebrikizumab Q2W	wotvbphhen(pwnfcldxvs) = hbuxkersry dwxuywhqqw (gpeknnccpq ) View more	Positive	13 Jul 2024
				Lebrikizumab Q4W	wotvbphhen(pwnfcldxvs) = zfrfupmrbg dwxuywhqqw (gpeknnccpq ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data